Get the Stockscreener App
13.92
0.50%
-0.07
After Hours:
13.92
Theravance Biopharma Inc stock is traded at $13.92, with a volume of 373.28K.
It is down -0.50% in the last 24 hours and down -2.66% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$13.99
Open:
$14.02
24h Volume:
373.28K
Relative Volume:
1.00
Market Cap:
$701.03M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-15.13
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
-4.53%
1M Performance:
-2.66%
6M Performance:
+65.71%
1Y Performance:
+67.51%
1-Day Range:
$13.75
$14.10
1-Week Range:
$13.75
$14.71
52-Week Range:
$7.90
$15.15
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
13.92 | 704.55M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-25 | Initiated | B. Riley Securities | Buy |
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Theravance Biopharma Inc. stock volume spike explainedTrade Signal Summary & Daily Profit Maximizing Tips - newser.com
Can Theravance Biopharma Inc. (0TB) stock hit consensus price targetsJuly 2025 Volume & Low Drawdown Investment Ideas - newser.com
Top chart patterns to watch in Theravance Biopharma Inc.Portfolio Performance Summary & Fast Moving Stock Trade Plans - newser.com
Why Theravance Biopharma Inc. stock is in analyst buy zone2025 Year in Review & Daily Profit Maximizing Tips - newser.com
Can Theravance Biopharma Inc. stock deliver consistent earnings growth2025 Risk Factors & Safe Capital Allocation Plans - newser.com
Will breakout in Theravance Biopharma Inc. lead to full recovery2025 Historical Comparison & Long-Term Capital Growth Strategies - newser.com
Leading vs lagging indicators on Theravance Biopharma Inc. performanceTrend Reversal & Fast Exit/Entry Strategy Plans - newser.com
Theravance Biopharma Hits New 52-Week High of $15.15, Up 67.59% - Markets Mojo
How to integrate Theravance Biopharma Inc. into portfolio analysis tools2025 Market Sentiment & AI Forecast Swing Trade Picks - newser.com
Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $23.00 - Defense World
Relative strength of Theravance Biopharma Inc. in sector analysisEarnings Recap Report & Entry Point Confirmation Alerts - newser.com
Is Theravance Biopharma Inc. (0TB) stock positioned for secular growthJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
What analysts say about Theravance Biopharma Inc stockInsider Trading Compliance & Build Capital Safely - earlytimes.in
Theravance Biopharma (NASDAQ:TBPH) Earns "Hold (C)" Rating from Weiss Ratings - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Earns “Hold (C)” Rating from Weiss Ratings - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Sets New 12-Month HighTime to Buy? - MarketBeat
Identifying reversal signals in Theravance Biopharma Inc.Weekly Stock Report & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-10-06 07:12:34 - newser.com
Can swing trading help recover from Theravance Biopharma Inc. lossesWeekly Risk Summary & Weekly Watchlist for Hot Stocks - newser.com
Will Theravance Biopharma Inc. benefit from macro trendsJuly 2025 Spike Watch & Low Risk High Win Rate Picks - newser.com
How to manage a losing position in Theravance Biopharma Inc.Watch List & Verified Short-Term Plans - newser.com
Can Theravance Biopharma Inc. (0TB) stock double in coming years2025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com
What insider purchases suggest about Theravance Biopharma Inc. (0TB) stockProduct Launch & Weekly High Conviction Ideas - newser.com
Published on: 2025-10-03 07:08:04 - newser.com
What RSI levels show for Theravance Biopharma Inc. (0TB) stock2025 Top Decliners & Risk Controlled Daily Plans - newser.com
Theravance Biopharma Inc. stock momentum explainedWeekly Loss Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Voya Investment Management LLC Reduces Stock Holdings in Theravance Biopharma, Inc. $TBPH - Defense World
Theravance Biopharma, Inc. $TBPH Shares Bought by Ballentine Partners LLC - Defense World
Theravance Biopharma Hits New 52-Week High of $14.87, Up 67.82% - Markets Mojo
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):